Author

Nadia Badri

Institution: PharmaMar (Spain)

Observed institution: PharmaMar (Spain)

OpenAlex ID: A5111626795

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

2013 · Jean-Yves Blay, Antoine Italiano, et al. · BMC Cancer · 77

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

2015 · B Colmegna, S Uboldi, et al. · British Journal of Cancer · 46

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

2013 · Bradley J. Monk, Stanley B. Kaye, et al. · Gynecologic Oncology · 9

Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcoma (ASTS).

2014 · Axel Le Cesne, Jean-Yves Blay, et al. · Journal of Clinical Oncology · 5

Exploratory analysis of nibrin in advanced ovarian cancer (AOC) patients treated in the phase III OVA-301 trial.

2013 · Miguel Aracil Avila, Antonio Nieto, et al. · Journal of Clinical Oncology · 2

Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS).

2012 · Maurizio D'Incalci, Carlos Galmarini, et al. · Journal of Clinical Oncology · 2

Abstract C93: Collateral sensitivity to cisplatin of trabectedin-resistant cell lines.

2013 · Maurizio D'Incalci, Benedetta Colmegna, et al. · Molecular Cancer Therapeutics · 1

Works count: 8

Citation count: 142

H-index: 4

I10-index: 2